Arbutus Biopharma (ABUS)
(Delayed Data from NSDQ)
$3.77 USD
+0.04 (1.07%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $3.76 -0.01 (-0.27%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.77 USD
+0.04 (1.07%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $3.76 -0.01 (-0.27%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Zacks News
Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Arbutus (ABUS) delivered earnings and revenue surprises of 0% and 46.45%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Albireo Pharma (ALBO) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Albireo Pharma (ALBO) delivered earnings and revenue surprises of -1.61% and 1.58%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arbutus (ABUS) delivered earnings and revenue surprises of 23.08% and 165.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Bristol Myers (BMY) delivered earnings and revenue surprises of 7.82% and 3.72%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
All You Need to Know About Arbutus (ABUS) Rating Upgrade to Buy
by Zacks Equity Research
Arbutus (ABUS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arbutus (ABUS) delivered earnings and revenue surprises of 15.38% and 118.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of -50.57% and 87.99%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Arbutus Biopharma (ABUS) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Arbutus (ABUS) delivered earnings and revenue surprises of 6.25% and 5.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Axsome (AXSM) Posts Narrower-Than-Expected Q4 Loss
by Zacks Equity Research
Axsome Therapeutics (AXSM) reports a narrower-than-expected Q4 loss. The company is actively preparing to support the commercial launch of its two under-review candidates, AXS-05 and AXS-07.
Aerie (AERI) Q4 Earnings Beat Estimates, Revenues Up Y/Y
by Zacks Equity Research
Aerie (AERI) beats earnings and sales estimates for the fourth quarter of 2021. AERI's shares increase in the after-market trading session following the news.
Intellia (NTLA) Q4 Loss Wider Than Expected, Revenues Up Y/Y
by Zacks Equity Research
Intellia Therapeutics (NTLA) reports wider-than-expected Q4 loss. Nonetheless, revenues beat estimates.
Agios (AGIO) Loss Wider Than Expected in Q4, Revenues Nil
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) posts wider-than-expected loss for the fourth quarter of 2021. It does not record any revenues in the quarter.
Halozyme Therapeutics (HALO) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 5% and 5.05%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of -1.34% and 3.26%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Do Options Traders Know Something About Arbutus Biopharma (ABUS) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.
Anixa (ANIX) COVID Compounds Prove Effective Against Omicron
by Zacks Equity Research
Anixa Biosciences' (ANIX) potential COVID-19 compounds show effectiveness against the Omicron variant of COVID-19.
Implied Volatility Surging for Arbutus Biopharma (ABUS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.
Arbutus Biopharma (ABUS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arbutus (ABUS) delivered earnings and revenue surprises of 0.00% and 41.53%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Arbutus Biopharma (ABUS) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Do Options Traders Know Something About Arbutus Biopharma (ABUS) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.
Is the Options Market Predicting a Spike in Arbutus Biopharma (ABUS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Arbutus Biopharma (ABUS) stock based on the movements in the options market lately.
Arbutus Biopharma (ABUS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arbutus (ABUS) delivered earnings and revenue surprises of -9.52% and 12.35%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Arbutus (ABUS) delivered earnings and revenue surprises of 4.55% and -45.40%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Arbutus (ABUS) delivered earnings and revenue surprises of -9.52% and 12.49%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Arbutus Biopharma (ABUS) This Earnings Season?
by Zacks Equity Research
Arbutus Biopharma (ABUS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.